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Disease activity (SLEDAI)Abstract Aim of the work: This work was designed to study the production of proinﬂammatory
cytokines in SLE patients and their correlation with disease activity and study if they can be used as
biomarkers for renal activity in lupus nephritis patients.
Patients and methods: This study was carried out on 70 subjects divided into two groups: Group I
(SLE group) which included 40 SLEpatients andGroup II (Control group)which included 30 apparently
healthy controls. The patients were subjected to full history taking and complete clinical examination.
Assessment of disease activity in SLE patients by Systemic Lupus Erythematosus Disease Activity Index
(SLEDAI). Sera of patients and controls were screened for the level of cytokine expression of T helper
cells including interleukin 17 (IL-17), interleukin 4 (IL-4) and interferon gamma (IFN-c).
Results: Serum levels of IL-4 were signiﬁcantly lower while both IL-17 and IFN-c were signiﬁcantly
higher in SLE patients than in the control group. The most powerful predictor and correlated cytokine
with the SLEDAI in SLE patients was IL-17. Higher serum level of IFN-c was associated with more
pyuria and hematuria, while higher IL-17 was associated with more pyuria and proteinuria in SLE
patients.
Conclusion: The serum level of IL-17 and IFN-cwas proven to be signiﬁcantly higher in SLE patients
and can be used as biomarkers of renal activity.
 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society for Joint Diseases and
Arthritis.Open access under CC BY-NC-ND license.1. Introduction
Systemic Lupus Erythematosus (SLE) is an autoimmune
disease associated with chronic immune activation and tissue
damage that results from the deposition of immune complexes
and inﬁltration of activated T cells into susceptible organs [1].
22 E.A. Elewa et al.Cytokines are soluble factors which play a role in differentia-
tion, maturation, and activation of various immune cells. They
are not only involved in immune dysregulation of SLE, but
also in local inﬂammatory response leading to tissue injury
[2]. These cytokines may exert either pro or anti-inﬂammatory
effects, or both, depending on speciﬁc local microenvironment,
thus contributing greatly to SLE pathogenesis. Understanding
these cytokine abnormalities may be beneﬁcial in developing
effective targeting therapeutics [3]. Cytokines play an impor-
tant role in lupus nephritis, so use of cytokines as biomarkers
of disease activity in SLE and lupus nephritis is of particular
interest [2]. T cells can be subdivided by the patterns of cyto-
kine released into: (1) Th1 cells produce IL-2 and IFN-c, which
are critical for cell-mediated immunity. (2) Th2 cells produce
IL-4, IL-5 and IL-10, which promote antibody production
and humoral immunity. (3) Th17 cells produce IL-17 [4].
IFN-c is generated by both innate and acquired immune
cells, particularly T cells and natural killer (NK) cells. It is
commonly accepted that IFN-c can promote Th1 polarization,
facilitate speciﬁc cytotoxicity by increasing the expression of
MHC class-I and -II molecules, and boost antigen processing
and immunoglobulin switching [5]. Targeting therapy for
IFN-c has been successfully applied to lupus mice, and
treatment with humanized anti-IFN-c mAb or recombinant
IFN-c-Ig fusion protein may provide a novel therapeutic
strategy for this intractable disease in human [6].
IL-4 is a 17 kDa monomeric glycoprotein of the type hema-
topoietin superfamily secreted by Th2 cells, NK T cells, mast
cells and basophils [7]. It plays a central role in regulating
the differentiation of antigen-stimulated naive T cells to devel-
op into IL-4-producing Th2 through IL-4R-mediated signaling
[8]. IL-4 is a multifunctional cytokine. Although most studies
have focused on the B-cell stimulatory and Th2 promoting
properties of IL-4 in the development of autoantibodies and
autoantibody-mediated diseases, a few reports suggest a T-cell
suppressor role for this cytokine in lupus. These properties of
IL-4 may sometimes result in opposing outcomes, amplifying
or inhibitory, on overall B-cell functions [9].
IL-17 is a type I transmembrane protein isolated initially from
a rodent CD4+T cell DNA library [10]. It ismainly produced by
activated Th17 cells which are in fact a subset of CD4+ T lym-
phocytes named after its hallmark cytokine IL-17. Recent data
indicate that IL-17 driven inﬂammation ampliﬁes SLE-induced
tissuedamage and contributes to tolerancebreakdown inSLEpa-
tients [11]. Elevated IL-17 levels in SLE probably contribute to
the recruitment and activation of immune cells (e.g., neutrophils
and T cells) to target organs and thus amplify immune response
[12]. The purpose of this work was to study the production of
the cytokines in SLE patients and their correlation with disease
activity and study if these cytokines can be used as biomarkers
for renal activity in lupus nephritis patients.
2. Patients and methods
This study was carried out in Rheumatology and Rehabilita-
tion Department, Faculty of Medicine, Zagazig University
on 70 subjects divided into two groups: Group I (SLE group)
which included 40 SLE patients diagnosed according to the
American College of Rheumatology (ACR) classiﬁcation crite-
ria for SLE [13]. Group II (Control group) included 30 appar-
ently healthy controls. Clinical examination as well as routine
laboratory investigations conﬁrmed their healthy state.Written informed consent was obtained from all patients
and controls for their study participation. The study was
approved by the local ethics committee of Zagazig University
Hospitals.
2.1. Clinical examination
Patients were subjected to full history taking and complete
clinical examination including general, locomotor system,
skin, cardiovascular, chest, neurological and vascular
examinations.
2.2. Disease activity
The disease activity was assessed in SLE patients by Systemic
Lupus Erythematosus Disease Activity Index (SLEDAI) [14].
Activity categories were deﬁned on the basis of SLEDAI
scores [15]; No activity (SLEDAI; 0), Mild activity (SLEDAI;
1–5), Moderate activity (SLEDAI; 6–10), High activity (SLE-
DAI; 11–19), and Very high activity (SLEDAI; 20).
2.3. Investigations
Investigations included are complete blood picture, erythro-
cyte sedimentation rate, C-reactive protein, complete urine
analysis, 24 h proteinuria, liver and kidney function tests,
Complement 3 (Normal value: 87–187 mg/dl), Complement 4
(Normal value: 16–38 mg/dl), ANA, and Anti DNA double
stranded antibody (Positive value up to 25 IU/ml).
2.4. Cytokines assay
Blood samples from patients and controls were centrifuged
and the sera screened for the level of cytokine expression of
T helper cells including interleukin 17, interleukin 4 and inter-
feron gamma (IFN-c). Sera were analyzed for cytokines by
sandwich enzyme-linked immunosorbent assay (ELISA)
according to the manufacturer’s protocols. IL-4 assay by Ani
Biotech Oy, Orgenium Laboratories Business Unit, Finland,
Product code IL10001, IL04001 and IL13001. Assay range:
15.6–250 pg/ml. IFN-c assay by Invitrogen, USA, Catalog
No. KAC1231. Assay range: 0–1.2 IU/ml. IL-17 assay by
WKEA MED supplies, USA. Assay range: 0.5–15 ng/L.
Statistical analysis: It was performed using SPSS statistical
software, version 11.0 (SPSS, Chicago, IL). Quantitative vari-
ables were given as means ± SD, medians, range and categor-
ical variables in frequencies and percents. t Test or the
Wilcoxon rank-sum tests were used for continuous variables
according to the distribution of the variable and the v2-test
for categorical variables. Measures the closeness of the associ-
ation between two quantitative continuous variables by corre-
lation coefﬁcient. Kruskall Wallis one way analysis of
variance (KW) test was used to compare median for >2 inde-
pendent samples that are not related. P value less than 0.05 was
considered statistically signiﬁcant.
3. Results
3.1. Demographic data of patients and control groups
Demographic data of patients and control groups are pre-
sented in Table 1.
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Figure 2 Laboratory investigations among the SLE patients.
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It was observed that the most frequent clinical variables
among SLE patients at the time taking samples were malar
rash, arthritis then fever representing (77.5%), (60%) and
(55%), respectively and the least frequent clinical variables
are cranial nerve affection and organic brain syndrome form-
ing 0% for both. Visual changes were observed in 2.5% in
the form of retinal changes, cytoid bodies, retinal hemor-
rhages, serous exudate or hemorrhage in choroid, optic neuri-
tis (not due to hypertension, drugs, or infection) (Fig. 1).
3.3. Laboratory investigations among SLE patients
Laboratory investigations among SLE patients are presented
in Fig. 2.
3.4. Disease activity of SLE patients
The median SLEDAI of our SLE patients was 8 with a range
from 0 to 30. Percentage of activity categories is represented in
graph, while inactive category was 5%. The majority of our
patients had moderate activity of the disease (Fig. 3).
3.5. Serum levels of cytokines in SLE and control group
Comparison between the serum levels of IL-4, IL-17 and
IFN-c in SLE and control group revealed that serum levels
of IL-4 were signiﬁcantly lower in SLE patients than in normal
subjects. The serum levels of both IL-17 and IFN-c in SLE
patients were signiﬁcantly higher than the levels in the control
group Table 2.
3.6. Sensitivity and speciﬁcity of cytokines in SLE patients
IL-4 was found to be the most sensitive cytokine among SLE
patients (Table 3).
3.7. Association between serum cytokine levels and clinical
presentations in SLE patients
There was an association between elevated IL-17 levels and
vasculitis (in the form of ulceration, gangrene, tender ﬁnger
nodules, periungual infarction, splinter hemorrhages),
mucocutaneous manifestations and serositis. Elevated serumTable 1 Demographic data of patients and control groups.
Item Patients
(n= 40)
Control
(n= 30)
T p
Age (years)
Range 17–50 20–53 t= 1.04 0.68 (NS)
Mean ± SD 31 ± 9.95 27 ± 10.4
Sex F/M 38/2 29/1 0.12 (X2) 0.74 (NS)
Disease duration (years)
Range 1–20 –
Median 3 –
p> 0.05 = Non signiﬁcant (NS), p< 0.05 = signiﬁcant.IFN-c was found to be associated with arthritis and mucocu-
taneous manifestations. IL-4 was found to have no association
with any of the clinical presentations of SLE (not shown).
3.8. Correlation of serum cytokines levels with anti-dsDNA, C3,
C4 and SLEDAI
There was no correlation of IL-4 serum level with SLEDAI, or
any of the laboratory parameters in SLE group, while there
was a signiﬁcant correlation between serum levels of both
IL-17 and IFN-c as well as the SLEDAI and anti-dsDNA.
There was a negative signiﬁcant correlation between C4 and
both IL-17 and IFN-c. Correlation of the levels of the three
cytokines with C3 showed that only IL-17 was negatively cor-
related (Table 4).
Figure 3 SLE Disease Activity Index (SLEDAI) subgroups of
SLE patients.
Table 2 Serum levels of cytokines IL-4, IL-17 and IFN-c in
SLE and control group.
Cytokine Patients (n= 40) Control (n= 30) P
IL-4 (pg/ml) 1.2 ± 0.6 (0.1–4.3) 4.4 ± 0.83 (3.1–5.9) 0.00*
IL-17 (ng/L) 37 (0.5–102) 6.75 (0.5–14) 0.00**
IFN-c (IU/ml) 0.7 (0.2–1.7) 0.29 (0.2–0.37) 0.00**
IL: interleukin, IFN-c: interferon gamma.
* t-test.
** Mann–whitney test.
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From Table 5 serum concentrations of IL-4 were not
signiﬁcantly different among the ﬁve subgroups of SLEDAI
(p= 0.33), while there were signiﬁcant differences in serum
concentrations of both IL-17 and IFN-c between mild activity
and very high activity groups with serum concentration of
both cytokines being signiﬁcantly higher in very high activity
group. By entering the previous correlated factors with
SLEDAI in the multiple forward stepwise logistic
regression analysis, we found that IL-17 is the most powerful
predictor and correlated cytokine with the SLEDAI in SLE
patients.
3.10. Association between serum cytokine levels and renal
activity descriptors of the SLEDAI
It was revealed that higher serum level of IFN-c was associated
with more pyuria and hematuria, while higher IL-17 was asso-
ciated with more pyuria and proteinuria in the SLE patients
(Table 6).Table 3 Diagnostic properties of IL17, IL-4, and IFN-c assays usi
Assay (cut oﬀ) Sensitivity (%) Speciﬁcity (%) PPV
IL-17 (P11.5) 77.5 83.3 86.1
IL-4 (62.5) 100 100 100
IFN-c (P0.38) 97.5 100 100
IL: interleukin, IFN-c: interferon gamma, PPV: positive predictive value
CI: conﬁdence interval.4. Discussion
In our work, we revealed that IL-4 is the most sensitive cyto-
kine in SLE patients and by comparing between its serum lev-
els in SLE and control group, they were signiﬁcantly lower in
SLE patients. This was in agreement with other studies [16–18]
who found a suppressed expression of Th2 cytokine IL-4 in
SLE patients. Also, Csiszaˆr et al. [19] found that the number
of mRNA transcripts of IL-4 decreased signiﬁcantly in the
SLE group. On the other hand, there was an increased serum
level of IL-4 in SLE patients in other studies [20,21]. While,
similar levels of IL-4 in SLE patients compared with controls
were observed by others [22,23]. IL-4 promotes antibody pro-
duction by B cells, so it is expected to have higher levels in SLE
patients. But its levels may not increase, as in our study, and
this may be due to that IL-4 provides B cell help for non-com-
plement-ﬁxing antibodies while in SLE autoantibodies are of
complement-ﬁxing type [19]. In addition, there is Th1 predomi-
nence in SLE patients and this Th1/Th2 imbalance may limit
the secretion of IL-4 levels [18]. There were elevated serum
IL-17 levels among SLE group more than in the control group
and this ﬁnding was in agreement with other different studies
[14,21,24,25].
Serum levels of IFN-c in SLE group were signiﬁcantly
higher than in normal subjects. Other studies go ahead with
our results [19,20,22]. In contrast to our study, Yu and Wang
[26] reported that the levels of IFN-c were lower in SLE group
than in control group. They explained their result by that Th1
or Th2 cells may have different functions in different phases of
the disease. Besides, it can be explained by the small number of
patients in their study which was only 20 and the short disease
duration ranging between 1 and 35 months.
In correlation of serum cytokine levels with anti-dsDNA,
we found that there was a signiﬁcant positive correlation with
IL-17 and this was in agreement with Dong et al. [27] who re-
ported that the increase in anti-dsDNA induced by IL-17 was
dose-dependent and could be completely blocked by IL-17
monoclonal antibody, but it cannot induce the peripheral
blood mononuclear cell (PBMC) of normal controls to aug-
ment anti-dsDNA secretion. This suggested that the IL-17 ef-
fect on increased anti-dsDNA level by PBMC may be
dependent on the characteristics of immunological and genetic
abnormalities occurring in PBMC of lupus nephritis patients.
IFN-c had a signiﬁcant positive correlation with anti-dsDNA
titer which was supported by other studies [7,28]. On the other
hand, no correlation between IL-4 and anti-dsDNA in SLE
patients was in agreement with Csiszaˆr et al. [19].
Serum concentrations of IL-4 were not signiﬁcantly differ-
ent among the ﬁve subgroups of SLEDAI and there was no
correlation between IL-4 and SLEDAI. Our results were con-
sistent with other studies [19,22,29] and inconsistent with theng optimal cutoff values.
(%) NPV (%) AUC 95% CI P
73.5 0.811 0.701–0.922 <0.05
100 0.25 0.000–0.073 <0.05
96.7 0.975 0.927–1.000 <0.05
, NPV: negative predictive value, AUC: area under the ROC curve,
Table 4 The correlation between serum cytokine levels and
anti-dsDNA, C3, C4 and SLEDAI.
Item IL-4 IL-17 IFN-c
r p r p r p
Anti-dsDNA 0.26 0.10 0.59 0.000* 0.55 0.03*
C3 0.26 0.1 3.34 0.03* 0.00 0.98
C4 1.4 0.39 0.65 0.04* 0.49 0.02*
SLEDAI 0.10 0.52 0.85 0.01* 0.51 0.02*
IL: interleukin, IFN-c: interferon gamma, C: complement, SLE-
DAI: SLE Disease Activity Index.
* Signiﬁcant.
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an inactive group. Our different results may be due to that
their study was on IL-4 production by NK T cells of SLE pa-
tients and not serum level. There was a signiﬁcant positive cor-
relation between serum levels of IFN-c and SLEDAI and there
were signiﬁcant differences in serum concentrations of IFN-c
between mild and very high activity groups being signiﬁcantlyTable 6 Association between serum cytokine levels and renal activ
Sterile pyuria Absent (n= 28)
Present (n= 12)
p**
Cast Absent (n= 34)
Present (n= 6)
p**
Hematuria Absent (n= 31)
Present (n= 9)
p**
Proteinuria (>0.5 g/24 h urine) Absent (n= 15)
Present (n= 25)
p**
IL: interleukin, IFN-c: interferon gamma.
* p< 0.05, signiﬁcant.
** Mann–whitney test.
 Urinary tract infections were excluded.
Table 5 Comparison between serum cytokine levels among SLEDA
Cytokine SLEDAI
Inactive n= 2 Mild n= 9 Moderate n
IL-17
Median (range) 7.75 20 30
(0.5–15) (0.5–29) (0.5–48)
IL-4
Median (range) 0.25 0.99 1.0
(0.1–0.4) (0.4–1.9) (0.2–1.7)
IFN-c
Median (range) 0.4 0.4 0.7
(0.4–0.4) (0.07–1.1) (0.2–1)
IL: interleukin, IFN-c: interferon gamma, SLEDAI: SLE Disease Activit
* Signiﬁcant.
** Kruskall Wallis one way analysis of variance (KW) test.higher in the very high activity group. This was in agreement
with Gigante et al. [30], Csiszaˆr et al. [19], and Viallard et al.
[29]. On the other hand, El-Sayed et al. [22] and Harigai
et al. [31] found no correlation between IFN-c and SLEDAI.
There was a signiﬁcant correlation between IL-17 serum levels
and SLEDAI. This was consistent with Chen et al. [24] and
Doreau et al. [12], while, Zhao et al. [25] found no signiﬁcant
difference.
In our study, we found that the most powerful predictor
and correlated cytokine with the SLEDAI in SLE patients
was IL-17. This result was supported by many other studies
[12,21,24,25,32] who reported that IL-17 production is in-
creased in patients with SLE. Also, Nalbandian et al. [33] ex-
plained increased secretion of IL-17 as a consequence of
systemic inﬂammation and facilitated pathways that guide T
cell differentiation into IL-17-producing cells (either Th17 or
DN T cells) in SLE patients.
In our work, we found that IL-17 was associated with pro-
teinuria and pyuria in SLE patients. Our results were sup-
ported by the work of Crispin et al. [34] who reported that
IL-17 could be detected in signiﬁcant amounts in analyzed re-
nal biopsies from patients with lupus nephritis. On the otherity descriptors of the SLEDAI in the SLE patients.
IL-4 IL-17 IFN-c
0.9 (0.1–4.3) 29.5 (0.5–96) 0.6 (0.07–4.3)
0.95 (0.3–1.8) 62.5 (15–102) 0.95 (0.15–1.6)
0.96 0.03* 0.02*
0.9 (0.1–4.3) 32.5 (0.5–96) 0.7 (0.07–4.3)
0.83 (0.3–1.8) 57.5 (1.5–102) 0.85 (0.3–1.6)
0.97 0.35 0.51
0.9 (0.1–4.3) 30 (0.5–102) 0.7 (0.07–4.3)
1 (0.3–1.8) 65 (1.5–100) 1.1 (0.15–1.5)
0.92 0.75 0.04*
0.85 (0.1–1.5) 21.5 (0.5–83) 0.6 (0.4–1.62)
1 (0.2–4.3) 45 (7.5–102) 0.85 (0.07–4.3)
0.32 0.02* 0.07
I subgroups.
K** p
= 12 High n= 9 Very high n= 8
60 87.5 26.1 0.00*
(50–80) (1.5–10)
0.90 1.05 4.58 0.33
(0.3–4.3) (0.3–1.7)
0.91 1.45 22.2 0.00*
(0.15–4.3) (0.7–1.6)
y Index.
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ence in serum IL-17 level between SLE patients with and with-
out nephritis. The higher serum level of IFN-c was associated
with pyuria and hematuria.
This result was supported by the work of Peterson et al. [35]
who reported that the interferon gene signature had been
found in glomerular tissue, suggesting local organ involvement
of interferon c. Also, Gigante et al. [30] reported that urinary
IFN-c levels were correlated with disease activity. So, both
IFN-c and IL-17 were found to be associated with the
SLEDAI descriptors of renal activity indicating that they play
a role in lupus nephritis.
In conclusion, the serum level of IL-17 and IFN-c was pro-
ven to be signiﬁcantly higher in SLE patients and can be used
as biomarkers of renal activity.
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